About Proscia
Proscia is a company based in Philadelphia (United States) founded in 2014 by Nathan Buchbinder and Coleman Stavish. Proscia has raised $129.23 million across 8 funding rounds from investors including Avenue Capital Group, TEDCO and ROBO Global. The company has 85 employees as of December 31, 2022. Proscia offers products and services including Concentriq Enterprise Pathology Platform, Concentriq AP, and Concentriq AP-Dx. Proscia operates in a competitive market with competitors including PathAI, Viz.ai, Deepcell, Deciphex and Aignostics, among others.
- Headquarter Philadelphia, United States
- Employees 85 as on 31 Dec, 2022
- Founders Nathan Buchbinder, Coleman Stavish
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Proscia Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$129.23 M (USD)
in 8 rounds
-
Latest Funding Round
$50 M (USD), Series C
Mar 04, 2025
-
Investors
Avenue Capital Group
& 18 more
-
Employee Count
85
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Proscia
Proscia offers a comprehensive portfolio of products and services, including Concentriq Enterprise Pathology Platform, Concentriq AP, and Concentriq AP-Dx.
Platform for AI-driven pathology analysis in medical diagnostics.
Software for digitizing and analyzing anatomic pathology specimens.
AI tool for precise diagnostic use in pathology workflows.
People of Proscia
Unlock access to complete
Funding Insights of Proscia
Proscia has successfully raised a total of $129.23M across 8 strategic funding rounds. The most recent funding activity was a Series C round of $50 million completed in March 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Proscia
Proscia has secured backing from 19 investors, including venture fund and institutional investors. Prominent investors backing the company include Avenue Capital Group, TEDCO and ROBO Global.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment firm scaling software and technology companies from early to late stages.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Private equity and VC-based investment firm
|
Locked | Locked | Locked |
Investor details for Proscia
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Proscia
Investment portfolio details for Proscia
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Proscia
Detailed financials for Proscia
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Proscia Comparisons
Peer comparison for Proscia
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Proscia
Proscia operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PathAI, Viz.ai, Deepcell, Deciphex and Aignostics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of AI-based solutions for clinical diagnosis of cancer and other diseases
|
|
| Locked | Locked | Locked |
AI and cloud-powered software for stroke care coordination is developed.
|
|
| Locked | Locked | Locked |
AI-powered single cell classification and isolation technology for clinical research
|
|
| Locked | Locked | Locked |
Digital pathology software is developed for clinical and veterinary productivity.
|
|
| Locked | Locked | Locked |
AI-based pathology diagnostic software is provided for medical analysis.
|
|
| Locked | Locked | Locked |
AI-based tools for pathological image analysis are provided to labs.
|
Detailed competitors of Proscia
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Proscia
Complete news archive for Proscia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Proscia
Proscia was founded in 2014 and raised its 1st funding round 2 years after it was founded.
Proscia is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Proscia is a funded company, having raised a total of $129.23M across 8 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Proscia is 85.
Proscias is a cloud-based software platform that clinic management, analysis, access, and collaboration for slide images in digital pathology. The features of the Proscia platform that allow users to improve whole slide image workflows include secure storage, annotation, and collaboration on digital biopsies. The company has developed a digital pathology platform called Concentriq that uses AI technology for computational pathology applications. The company has developed a tool that assists helathacre providers to diagnose cancer cells using image analysis technology.
Proscia's top competitors include Aignostics, Deciphex and Pictor Labs.
Proscia offers Concentriq Enterprise Pathology Platform, Concentriq AP, and Concentriq AP-Dx.
Proscia has 19 investors. Key investors include Avenue Capital Group, TEDCO, ROBO Global, Insight Partners, and AI Capital.